Only Skin Deep? Psoriasis, Psoriatic Arthritis and Periodontitis

Only Skin Deep? Psoriasis, Psoriatic Arthritis and Periodontitis

Periodontitis (CP) is a multifactorial chronic inflammatory disease that has a strong bidirectional relationship with diabetes mellitus, associations with cardiovascular disease and Alzheimer’s disease, and links to other systemic diseases.1Sanz M, Ceriello A, Buysschaert M et al. Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. J Clin Periodontol 2018;45(2):138-49. doi: 10.1111/jcpe.12808. ^,2Genco RJ, Sanz M. Clinical and public health implications of periodontal and systemic diseases: An overview. Periodontol 2000 2020;83(1):7-13. doi: 10.1111/prd.12344. In addition, several systemic chronic inflammatory conditions and CP frequently co-exist in individuals, with higher levels of inflammatory responses than the general population.3Bunte K, Beikler T. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. Int J Mol Sci2019;20(14):3394. doi: 10.3390/ijms20143394. A significant amount of research now also exists for a relationship between CP and rheumatoid arthritis.4González-Febles J, Sanz M. Periodontitis and rheumatoid arthritis: What have we learned about their connection and their treatment? Periodontol 2000 2021;87(1):181-203. doi: 10.1111/prd.12385. Emerging science suggests a potential association for psoriasis (Ps), psoriatic arthritis (PsA) and CP, which are the most frequently occurring chronic inflammatory diseases.5Mendes VS, Cota LOM, Costa AA et al. Periodontitis as another comorbidity associated with psoriasis: A case-control study. J Periodontol 2019;90(4):358-66. doi: 10.1002/JPER.18-0394.^,6Sezer U, Şenyurt SZ, Gündoğar H et al. Effect of Chronic Periodontitis on Oxidative Status in Patients With Psoriasis and Psoriatic Arthritis. J Periodontol 2016;87(5):557-65. doi: 10.1902/jop.2015.150337. In this article we will review available information on psoriatic disease and its potential association with CP.

Ps and PsA
Ps is a chronic autoimmune disorder involving a dysregulated immune response, with a prevalence of around 3% globally.7Üstün K, Sezer U, Kısacık B et al. Periodontal disease in patients with psoriatic arthritis. Inflammation 2013;36(3):665-9. doi: 10.1007/s10753-012-9590-y.^,8Crincoli V, Di Comite M, Di Bisceglie MB et al. Temporomandibular Disorders in Psoriasis Patients with and without Psoriatic Arthritis: An Observational Study. Int J Med Sci 2015;12(4):341-8. doi:10.7150/ijms.11288^,9Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol 2017;49:1-8.^,10Yan D, Gudjonsson JE, Le S et al. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. J Invest Dermatol 2021;141(9):2112-22.e3. doi: 10.1016/j.jid.2021.02.764. Ps can involve the skin (including the scalp), nails, and mucous membranes, and includes subtypes. In skin, an inflammatory process causes the production of excessive levels of keratinocytes which results in thickened plaque-like irritated areas. (Figure 1) This presentation is also referred to as plaque Ps. However, subtype inverse Psoriasis presents as a red, shiny, smooth rash in skin folds. Abnormal papillary capillaries and neovascularization also occur at the site of Ps lesions, as well as intraepidermal neutrophil micro-abscess.9Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol 2017;49:1-8. Psoriatic inflammation exhibits periods of exacerbation and remission. Risk factors include a strong genetic component and environmental triggers including emotional stress, alcohol consumption, medications, skin trauma, infections, biomechanical stress, obesity, and endocrine disorders.10Yan D, Gudjonsson JE, Le S et al. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. J Invest Dermatol 2021;141(9):2112-22.e3. doi: 10.1016/j.jid.2021.02.764.^,11Gonzaga HF, Chaves MD, Gonzaga LH et al. Environmental factors in benign migratory glossitis and psoriasis: retrospective study of the association of emotional stress and alcohol and tobacco consumption with benign migratory glossitis and cutaneous psoriasis. J Eur Acad Dermatol Venereol 2015;29(3):533-6. doi: 10.1111/jdv.12616. (Table 1)

Patients with Ps can also develop PsA. The prevalence of PsA in patients with Ps is around 30%, with a range from 5% to 70% cited in the literature.5Mendes VS, Cota LOM, Costa AA et al. Periodontitis as another comorbidity associated with psoriasis: A case-control study. J Periodontol 2019;90(4):358-66. doi: 10.1002/JPER.18-0394.^,9Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol 2017;49:1-8.^,12Badel T, Savić Pavičin I, Krapac L et al. Psoriatic arthritis and temporomandibular joint involvement – literature review with a reported case. Acta Dermatovenerol Croat 2014;22(2):114-21. PsA is a chronic seronegative arthritis, usually preceded by psoriasis, and results in progressive inflammatory joint damage.7Üstün K, Sezer U, Kısacık B et al. Periodontal disease in patients with psoriatic arthritis. Inflammation 2013;36(3):665-9. doi: 10.1007/s10753-012-9590-y.^,13Sakkas LI, Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev 2017;16(1):10-5. doi: 10.1016/j.autrev.2016.09.015.

The Inflammatory Cascade
The development and progression of Ps results from an immune-driven inflammatory cascade involving cytokines and chemokines. The T helper 17 cell population (Th17), a subset of CD4 T cells, is maintained and increased by IL-23.14Malakouti M, Brown GE, Wang E et al. The role of IL-17 in psoriasis. J Dermatolog Treat 2015;26(1):41-4. doi: 10.3109/09546634.2013.879093. Th17 secrete IL-17 and IL-22. The IL-23/IL-17 pathway is considered to have a key role in the development and progression of both PsA and Ps as well as other autoimmune conditions.13Sakkas LI, Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev 2017;16(1):10-5. doi: 10.1016/j.autrev.2016.09.015.^,14Malakouti M, Brown GE, Wang E et al. The role of IL-17 in psoriasis. J Dermatolog Treat 2015;26(1):41-4. doi: 10.3109/09546634.2013.879093. While IL-17F is protective against infections, IL-17A mediates the innate immune response but also acts as a pro-inflammatory cytokine.15Zenobia C, Hajishengallis G. Basic biology and role of interleukin-17 in immunity and inflammation. Periodontology 2000 2015;69:142-59. doi 10.1111/prd.12083.^,16Feng Y, Chen Z, Tu SQ et al. Role of Interleukin-17A in the Pathomechanisms of Periodontitis and Related Systemic Chronic Inflammatory Diseases. Front Immunol 2022;13:862415. doi: 10.3389/fimmu.2022.862415. IL-17A in turn promotes production of IL-1, IL-6, TNF-alpha and other pro-inflammatory factors. Overexpression of TNF-alpha causes rapid proliferation of keratinocytes (Ps) and bony destruction (PsA). Pro-inflammatory mediators such as matrix metalloproteinases (MMPs), RANKL and VEGF also result in tissue destruction. IL-12, IL-17, IL-22, and IL-23 are all involved in psoriatic inflammation.17National Psoriasis Foundation. Drugs that are associated with dry mouth. https://www.ehealthme.com/side-effect/dry-mouth/t/1/. Furthermore, higher levels of IL-22 are found in skin lesions (Ps) and connective tissues than in joints, and IL-22 promotes bone formation, while high levels of IL-17 have been found for PsA and Ps. 13Sakkas LI, Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev 2017;16(1):10-5. doi: 10.1016/j.autrev.2016.09.015.^,14Malakouti M, Brown GE, Wang E et al. The role of IL-17 in psoriasis. J Dermatolog Treat 2015;26(1):41-4. doi: 10.3109/09546634.2013.879093. (Figure 2)

The inflammatory cascade associated with Th17 and IL-17/IL-23 is also involved in the development and progression of other systemic immune-related conditions as well as CP.3Bunte K, Beikler T. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. Int J Mol Sci2019;20(14):3394. doi: 10.3390/ijms20143394.^,18Beklen A, Ainola M, Hukkanen M et al. MMPs, IL-1, and TNF are Regulated by IL-17 in Periodontitis. J Dent Res 2007;86(4):347-51. doi:0.1177/154405910708600409. In addition, in recent research, higher levels of IL-17A, IL-22 and IL-23 have been found in the gingival crevicular fluid of patients with Ps and moderate/severe CP compared to individuals with mild CP or who are periodontally healthy.19Jiménez C, Carvajal D, Hernández M et al. Levels of the Interleukins 17A, 22, and 23 and the S100 Protein Family in the Gingival Crevicular Fluid of Psoriatic Patients With or Without Periodontitis. Bras Dermatol 2021;96(2):163-70. doi: 10.1016/ j.abd.2020.08.008 In other research, higher concentrations of oral bacterial DNA were found in synovial fluid in patients with PsA (and patients with RA) than in other individuals.20Moen K, Brun JG, Valen M et al. Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. Clin Exp Rheumatol 2006;24(6):656-63. Porphyromonas gingivalis and Prevotella nigrescens were only found in the synovial fluids of patients with PsA or RA.

Studies on CP and Ps/PsA

Researchers have studied the potential influence of Ps and PsA on CP, and the potential influence of CP on Ps and PsA.

CP in individuals with Ps, PsA
In a quantitative meta-analysis of 8 studies conducted between 2013 and 2019, individuals with Ps were found to have poorer periodontal health and greater clinical attachment loss than individual without Ps.21Qiao P, Shi Q, Zhang R et al. Psoriasis Patients Suffer From Worse Periodontal Status-A Meta-Analysis. Front Med (Lausanne) 2019;6:212. doi: 10.3389/fmed.2019.00212. However, most studies were case control studies with varying study methodologies, weakening these findings. In a nationwide cohort study in Denmark, 5 million individuals at least 18 years-of-age between 1997 and 2011 were included.22Egeberg A, Mallbris L, Gislason G et al. Risk of periodontitis in patients with psoriasis and psoriatic arthritis. J Eur Acad Dermatol Venereol 2017;31(2):288-93. doi: 10.1111/jdv.13814. Risk for CP increased by more than half, double and triple, respectively, for individuals with mild Ps, severe Ps and PsA. In a nationwide retrospective cohort study in Taiwan, subjects included individuals diagnosed with psoriatic disease between 2003 and 2011 and individuals without Ps.23Su NY, Huang JY, Hu CJ et al. Increased risk of periodontitis in patients with psoriatic disease: a nationwide population-based retrospective cohort study. Peer J. 2017;5:e4064. doi: 10.7717/peerj.4064. A greater risk of developing CP and more severe CP was found for the group with PsA compared to individuals with or without Ps.

In a prospective case control study with 201 patients, individuals with Ps had greater periodontal inflammation.24Woeste S, Graetz C, Gerdes S, Mrowietz U. Oral Health in Patients with Psoriasis-A Prospective Study. J Invest Dermatol 2019;139(6):1237-44. doi: 10.1016/j.jid.2018.12.014. In another case control study, a higher prevalence of CP was found for patients with moderate/severe Ps compared to the control group.25Skudutyte-Rysstad R, Slevolden EM, Hansen BF et al. Association between moderate to severe psoriasis and periodontitis in a Scandinavian population. BMC Oral Health 2014;14:139. doi 10.1186/1472-6831-14-139. A 72% greater risk for CP was found for individuals with Ps in a recent case-control study with more than seven hundred individuals, and a greater prevalence of CP for more severe Ps.5Mendes VS, Cota LOM, Costa AA et al. Periodontitis as another comorbidity associated with psoriasis: A case-control study. J Periodontol 2019;90(4):358-66. doi: 10.1002/JPER.18-0394. In one study, researchers found a more than five-fold risk for CP for the group with inverse type Ps compared to the group with typical Ps.26Painsi C, Hirtenfelder A, Lange-Asschenfeldt B et al. The Prevalence of Periodontitis Is Increased in Psoriasis and Linked to Its Inverse Subtype. Skin Pharmacol Physiol 2017;30(6):324-8. doi: 10.1159/000481544. A higher prevalence of CP and more severe CP has also been found for patients with PsA compared to those without PsA.7Üstün K, Sezer U, Kısacık B et al. Periodontal disease in patients with psoriatic arthritis. Inflammation 2013;36(3):665-9. doi: 10.1007/s10753-012-9590-y.^,27Mishra S, Johnson L, Agrawal S, Rajput S. Assessment of Periodontal status in Patients with Psoriatic Arthritis: A retrospective, case-control study. J Clin Exp Dent 2021;13(8):e776-83. Conversely, one study found no increase in risk for CP in relation to the presence of Ps.28Fadel HT, Flytström I, Calander AM et al. Profiles of dental caries and periodontal disease in individuals with or without psoriasis. J Periodontol 2013;84(4):477-85. doi: 10.1902/jop.2012.120119. In a second study measuring antioxidant levels in patients with and without PS or PsA and with or without CP, clinical parameters were unaffected by Ps or PsA.6Sezer U, Şenyurt SZ, Gündoğar H et al. Effect of Chronic Periodontitis on Oxidative Status in Patients With Psoriasis and Psoriatic Arthritis. J Periodontol 2016;87(5):557-65. doi: 10.1902/jop.2015.150337.

Ps, PsA in individuals with CP
In a prospective cohort study with more than 60,000 nurses, risk for Ps in individuals with CP was evaluated.29Nakib S, Han J, Li T et al. Periodontal disease and risk of psoriasis among nurses in the United States. Acta Odontol Scand 2013;71:1423-9. doi: 10.3109/00016357.2013.766360. After adjusting for confounders (age, physical activity, tooth loss, body mass index, cigarette smoking and alcohol consumption), risk for developing Ps increased by 35% and 49% for individuals with mild and moderate/severe CP, respectively. One study limitation was that CP (bone loss) was self-reported. In a second cohort study with more than 230,000 individuals, at 5 years the risk of developing Ps was 52% higher for individuals with CP compared to the periodontally healthy group.30Keller JJ, Lin HC. The effects of chronic periodontitis and its treatment on the subsequent risk of psoriasis. Brit J Dermatol 2012;167:1338-44. Doi 10.1111/j.1365-2133.2012.11126.x. In a meta-analysis conducted to evaluate the potential association between Ps and CP, an almost three-fold risk for Ps was found for individuals with CP.31Zhang X, Gu H, Xie S, Su Y. Periodontitis in patients with psoriasis: A systematic review and meta-analysis. Oral Dis 2022;28(1):33-43. doi: 10.1111/odi.13617. However, studies used differing methodologies, did not all consider confounders, and seven of the 9 studies included were case controlled, weakening the findings. In a case control study conducted in 2013, Ps and CP were significantly correlated.32Lazaridou E, Tsikrikoni A, Fotiadou C et al. Association of chronic plaque psoriasis and severe periodontitis: a hospital based case-control study. J Eur Acad Dermatol Venereol 2013;27:967-72 doi 10.1111/j.1468-3083.2012.04615.x.

Effect of periodontal therapy
There is limited data on the effect of periodontal therapy on Ps and PsA. In a randomized controlled trial with subjects with CP and Ps, non-surgical periodontal therapy resulted in lower levels of IL-2 and IL-6 and less severe Ps eight weeks post-treatment compared to levels found for the control group awaiting periodontal therapy.33Ucan Yarkac F, Ogrum A, Gokturk O. Effects of non-surgical periodontal therapy on inflammatory markers of psoriasis: A randomized controlled trial. J Clin Periodontol 2020;47(2):193-201. doi: 10.1111/jcpe.13205. In one study, periodontal therapy reduced risk for future Ps.30Keller JJ, Lin HC. The effects of chronic periodontitis and its treatment on the subsequent risk of psoriasis. Brit J Dermatol 2012;167:1338-44. Doi 10.1111/j.1365-2133.2012.11126.x.

Oral manifestations of Ps and PsA

Oral manifestations reported are primarily geographic tongue (GT). (Figure 3) In a review of eleven case control studies, a three-fold prevalence of GT was found for patients with Ps compared to the control group.34González-Álvarez L, García-Martín JM, García-Pola MJ. Association between geographic tongue and psoriasis: A systematic review and meta-analyses. J Oral Pathol Med 2019;48(5):365-72. doi: 10.1111/jop.12840. In addition, individuals with GT exhibited more severe Ps in 3 of the 4 studies assessing this variable. In a recent case control study, more than three times as many oral lesions were seen in the Ps group than in the control group, specifically GT and angular cheilitis.35Costa AA, Cota LOM, Mendes VS et al. Impact of oral lesions on the quality of life of psoriatic individuals: A case-control study. Oral Dis 2021;27(7):1813-21. doi: 10.1111/odi.13695. Other studies report an increased prevalence of GT and fissured tongue in patients with Ps.36Picciani B, Santos T, Domingos C et al. Geographic tongue and fissured tongue in 348 patients with psoriasis: correlation with disease severity. Sci World J 2015;2015:564326.^,37Germi L, De Giorgi V, Bergamo F et al. Psoriasis and oral lesions: multicentric study of Oral Mucosa Diseases Italian Group (GIPMO). Dermatol Online J 2012:18(1): 11. ^,38Talaee R, Hajheydari Z, Moghaddam AY et al. Prevalence of Oral Mucosal Lesions and Their Association with Severity of Psoriasis among Psoriatic Patients Referred To Dermatology Clinic: A Cross-Sectional Study in Kashan/Iran. Open Access Maced J Med Sci 2017;5(7):978-82. doi: 10.3889/oamjms.2017.189.^,39Monson CA, Silva V, Porfírio G et al. Oral Health Issues in Psoriasis: An Overview of the Literature. Int J Clin Dermatol & Res 2016;94-103. Doi: 10.19070/2332-2977-1600025.^,40Olejnik M, Osmola-Mańkowska A, Ślebioda Z et al. Oral mucosal lesions in psoriatic patients based on disease severity and treatment approach. J Oral Pathol Med 2020;49(8):822-8. doi: 10.1111/jop.13095. Two studies resulted in the conclusion that GT may be a biomarker for Ps severity,36Picciani B, Santos T, Domingos C et al. Geographic tongue and fissured tongue in 348 patients with psoriasis: correlation with disease severity. Sci World J 2015;2015:564326.^,41Zargari O. The prevalence and significance of fissured tongue and geographical tongue in psoriatic patients. Clin and Exper Dermatol 2006;31(2):192-5. doi: 10.1111/j.1365-2230.2005.02028.x. while in another study no such relationship was found.40Olejnik M, Osmola-Mańkowska A, Ślebioda Z et al. Oral mucosal lesions in psoriatic patients based on disease severity and treatment approach. J Oral Pathol Med 2020;49(8):822-8. doi: 10.1111/jop.13095. More severe GT has been found in patients with Ps, and it was proposed that GT in these patients is oral psoriasis.42Picciani B, Santos VC, Teixeira-Souza T et al. Investigation of the clinical features of geographic tongue: unveiling its relationship with oral psoriasis. Int J Dermatol 2017;56(4):421-7. doi: 10.1111/ijd.13460. GT is a chronic, inflammatory and ‘immune-mediated’ condition, with an inflammatory process similar to Ps, including the role of Th17, IL-17 and IL-23.43Picciani BLS, Domingos TA, Teixeira-Souza T et al. Evaluation of the Th17 pathway in psoriasis and geographic tongue. An Bras Dermatol 2019;94(6):677-83. doi: 10.1016/j.abd.2019.01.006.

Researchers have found a significant increase in signs and symptoms of TMD (bruxism, limited opening, clicking sounds and orofacial pain) in patients with Ps, and more so in patients with PSA.8Crincoli V, Di Comite M, Di Bisceglie MB et al. Temporomandibular Disorders in Psoriasis Patients with and without Psoriatic Arthritis: An Observational Study. Int J Med Sci 2015;12(4):341-8. doi:10.7150/ijms.11288^,39Monson CA, Silva V, Porfírio G et al. Oral Health Issues in Psoriasis: An Overview of the Literature. Int J Clin Dermatol & Res 2016;94-103. Doi: 10.19070/2332-2977-1600025. Typical signs of PsA are found during magnetic resonance imaging, including bony erosions and articular effusion.12Badel T, Savić Pavičin I, Krapac L et al. Psoriatic arthritis and temporomandibular joint involvement – literature review with a reported case. Acta Dermatovenerol Croat 2014;22(2):114-21.

Other Considerations

Medications used to treat psoriatic disease include hydrocortisone, non-steroidal anti-inflammatories, methotrexate (an anti-neoplastic drug), cyclosporine (an immunosuppressant), retinoids (acitracin, Soriatane), and biologics.39Monson CA, Silva V, Porfírio G et al. Oral Health Issues in Psoriasis: An Overview of the Literature. Int J Clin Dermatol & Res 2016;94-103. Doi: 10.19070/2332-2977-1600025.^,44National Psoriasis Foundation. Soriatane (Acitretin). https://www.psoriasis.org/soriatane-acitretin/. Biologics currently used to treat psoriatic disease are delivered by injection.39Monson CA, Silva V, Porfírio G et al. Oral Health Issues in Psoriasis: An Overview of the Literature. Int J Clin Dermatol & Res 2016;94-103. Doi: 10.19070/2332-2977-1600025.^,45National Psoriasis Foundation. Current Biologics on the Market. https://www.psoriasis.org/current-biologics-on-the-market/. These include IL-17 inhibitors (Cosentyx, secukinumab; Siliq, brodalumab; Taltz, ixekizumab), an IL-12 and Il-23 inhibitor (Stelara, ustekinumab), IL-23 inhibitors (Ilumya, tildrakizumab-asmn; Skyrizi, risankizumab-rzaa; Tremfya, guselkumab), TNF-alpha inhibitors such as Enbrel (etanercept) and Humira (adalimumab), and a T-cell inhibitor (Orencia, abatacept).

The medication used depends on the type and severity of psoriatic disease. Oral adverse events may also occur.39Monson CA, Silva V, Porfírio G et al. Oral Health Issues in Psoriasis: An Overview of the Literature. Int J Clin Dermatol & Res 2016;94-103. Doi: 10.19070/2332-2977-1600025. Retinoids can cause dry mouth and gingival bleeding, cyclosporine can cause gingival hyperplasia, reports of mucositis have occurred with methotrexate use, and there have been reports of dry mouth for some biologics.18Beklen A, Ainola M, Hukkanen M et al. MMPs, IL-1, and TNF are Regulated by IL-17 in Periodontitis. J Dent Res 2007;86(4):347-51. doi:0.1177/154405910708600409. Drug contraindications and systemic adverse events are outwith the scope of this article.

Conclusions

CP and Ps/PsA are multifactorial chronic diseases with inflammatory cascades involving IL-17 and with other chemokines and cytokines in common. Risk factors also overlap. CP may play a role in the development or increased severity of Ps and it may also negatively impact the effectiveness of treatment for Ps.46Dalmády S, Kemény L, Antal M, Gyulai R. Periodontitis: a newly identified comorbidity in psoriasis and psoriatic arthritis. Expert Rev Clin Immunol 2020;16(1):101-8. doi: 10.1080/1744666X.2019.1700113. However, neither causality nor a strong association have yet been determined. Researchers have noted study weaknesses, including methodologies and heterogeneity. Well-designed prospective studies have been recommended to determine the relationship between CP and Ps/PsA.16Feng Y, Chen Z, Tu SQ et al. Role of Interleukin-17A in the Pathomechanisms of Periodontitis and Related Systemic Chronic Inflammatory Diseases. Front Immunol 2022;13:862415. doi: 10.3389/fimmu.2022.862415.^,21Qiao P, Shi Q, Zhang R et al. Psoriasis Patients Suffer From Worse Periodontal Status-A Meta-Analysis. Front Med (Lausanne) 2019;6:212. doi: 10.3389/fmed.2019.00212.^,31Zhang X, Gu H, Xie S, Su Y. Periodontitis in patients with psoriasis: A systematic review and meta-analysis. Oral Dis 2022;28(1):33-43. doi: 10.1111/odi.13617. Further research is also needed on the impact of non-surgical periodontal therapy on existing Ps/PsA, as well as potential improvement in CP with use of biologics to treat Ps and PsA.

In the meantime, patients with Ps/PsA should receive regular dental check-ups, including periodontal evaluations.23Su NY, Huang JY, Hu CJ et al. Increased risk of periodontitis in patients with psoriatic disease: a nationwide population-based retrospective cohort study. Peer J. 2017;5:e4064. doi: 10.7717/peerj.4064.^,24Woeste S, Graetz C, Gerdes S, Mrowietz U. Oral Health in Patients with Psoriasis-A Prospective Study. J Invest Dermatol 2019;139(6):1237-44. doi: 10.1016/j.jid.2018.12.014.^,46Dalmády S, Kemény L, Antal M, Gyulai R. Periodontitis: a newly identified comorbidity in psoriasis and psoriatic arthritis. Expert Rev Clin Immunol 2020;16(1):101-8. doi: 10.1080/1744666X.2019.1700113. Awareness of potential oral adverse events of Ps/PsA medication, preventive care for patients who may be experiencing dry mouth and treatment for other adverse events are important for oral health and quality of life. Dental professionals can help patients with Ps/PsA by educating them on the importance of preventing CP, the need to treat existing CP and to maintain oral health.

References

• 1.Dominy SS, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5(1):eaau3333 https://www.ncbi.nlm.nih.gov/pubmed/30746447.
• 2.Sadrameli M, et al. Linking mechanisms of periodontitis to Alzheimer’s disease. Curr Opin Neurol. 2020;33(2):230-8 https://www.ncbi.nlm.nih.gov/pubmed/32097126.
• 3.Borsa L, et al. Analysis the link between periodontal diseases and Alzheimer’s disease: A systematic review. Int J Environ Res Public Health. 2021;18(17) https://www.ncbi.nlm.nih.gov/pubmed/34501899.
• 4.Costa MJF, et al. Relationship of Porphyromonas gingivalis and Alzheimer’s disease: A systematic review of pre-clinical studies. Clin Oral Investig. 2021;25(3):797-806 https://www.ncbi.nlm.nih.gov/pubmed/33469718.
• 5.Munoz Fernandez SS, Lima Ribeiro SM. Nutrition and Alzheimer disease. Clin Geriatr Med. 2018;34(4):677-97 https://www.ncbi.nlm.nih.gov/pubmed/30336995.
• 6.Aquilani R, et al. Is the Brain Undernourished in Alzheimer’s Disease? Nutrients. 2022;14(9) https://www.ncbi.nlm.nih.gov/pubmed/35565839.
• 7.Fukushima-Nakayama Y, et al. Reduced mastication impairs memory function. J Dent Res. 2017;96(9):1058-66 https://www.ncbi.nlm.nih.gov/pubmed/28621563.
• 8.Kim HB, et al. Abeta accumulation in vmo contributes to masticatory dysfunction in 5XFAD Mice. J Dent Res. 2021;100(9):960-7 https://www.ncbi.nlm.nih.gov/pubmed/33719684.
• 9.Miura H, et al. Relationship between cognitive function and mastication in elderly females. J Oral Rehabil. 2003;30(8):808-11 https://www.ncbi.nlm.nih.gov/pubmed/12880404.
• 10.Lexomboon D, et al. Chewing ability and tooth loss: association with cognitive impairment in an elderly population study. J Am Geriatr Soc. 2012;60(10):1951-6 https://www.ncbi.nlm.nih.gov/pubmed/23035667.
• 11.Elsig F, et al. Tooth loss, chewing efficiency and cognitive impairment in geriatric patients. Gerodontology. 2015;32(2):149-56 https://www.ncbi.nlm.nih.gov/pubmed/24128078.
• 12.Kim EK, et al. Relationship between chewing ability and cognitive impairment in the rural elderly. Arch Gerontol Geriatr. 2017;70:209-13 https://www.ncbi.nlm.nih.gov/pubmed/28214402.
• 13.Kim MS, et al. The association between mastication and mild cognitive impairment in Korean adults. Medicine (Baltimore). 2020;99(23):e20653 https://www.ncbi.nlm.nih.gov/pubmed/32502052.
• 14.Cardoso MG, et al. Relationship between functional masticatory units and cognitive impairment in elderly persons. J Oral Rehabil. 2019;46(5):417-23 https://www.ncbi.nlm.nih.gov/pubmed/30614023.
• 15.Popovac A, et al. Oral health status and nutritional habits as predictors for developing alzheimer’s disease. Med Princ Pract. 2021;30(5):448-54 https://www.ncbi.nlm.nih.gov/pubmed/34348313.
• 16.Park T, et al. More teeth and posterior balanced occlusion are a key determinant for cognitive function in the elderly. Int J Environ Res Public Health. 2021;18(4) https://www.ncbi.nlm.nih.gov/pubmed/33669490.
• 17.Lin CS, et al. Association between tooth loss and gray matter volume in cognitive impairment. Brain Imaging Behav. 2020;14(2):396-407 https://www.ncbi.nlm.nih.gov/pubmed/32170642.
• 18.Kumar S, et al. Oral health status and treatment need in geriatric patients with different degrees of cognitive impairment and dementia: a cross-sectional study. J Family Med Prim Care. 2021;10(6):2171-6 https://www.ncbi.nlm.nih.gov/pubmed/34322409.
• 19.Delwel S, et al. Chewing efficiency, global cognitive functioning, and dentition: A cross-sectional observational study in older people with mild cognitive impairment or mild to moderate dementia. Front Aging Neurosci. 2020;12:225 https://www.ncbi.nlm.nih.gov/pubmed/33033478.
• 20.Da Silva JD, et al. Association between cognitive health and masticatory conditions: a descriptive study of the national database of the universal healthcare system in Japan. Aging (Albany NY). 2021;13(6):7943-52 https://www.ncbi.nlm.nih.gov/pubmed/33739304.
• 21.Galindo-Moreno P, et al. The impact of tooth loss on cognitive function. Clin Oral Investig. 2022;26(4):3493-500 https://www.ncbi.nlm.nih.gov/pubmed/34881401.
• 22.Stewart R, et al. Adverse oral health and cognitive decline: The health, aging and body composition study. J Am Geriatr Soc. 2013;61(2):177-84 https://www.ncbi.nlm.nih.gov/pubmed/23405916.
• 23.Dintica CS, et al. The relation of poor mastication with cognition and dementia risk: A population-based longitudinal study. Aging (Albany NY). 2020;12(9):8536-48 https://www.ncbi.nlm.nih.gov/pubmed/32353829.
• 24.Kim MS, Han DH. Does reduced chewing ability efficiency influence cognitive function? Results of a 10-year national cohort study. Medicine (Baltimore). 2022;101(25):e29270 https://www.ncbi.nlm.nih.gov/pubmed/35758356.
• 25.Ko KA, et al. The Impact of Masticatory Function on Cognitive Impairment in Older Patients: A Population-Based Matched Case-Control Study. Yonsei Med J. 2022;63(8):783-9 https://www.ncbi.nlm.nih.gov/pubmed/35914761.
• 26.Garre-Olmo J. [Epidemiology of Alzheimer’s disease and other dementias]. Rev Neurol. 2018;66(11):377-86 https://www.ncbi.nlm.nih.gov/pubmed/29790571.
• 27.Stephan BCM, et al. Secular Trends in Dementia Prevalence and Incidence Worldwide: A Systematic Review. J Alzheimers Dis. 2018;66(2):653-80 https://www.ncbi.nlm.nih.gov/pubmed/30347617.
• 28.Lopez OL, Kuller LH. Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer’s disease and other dementias. Handb Clin Neurol. 2019;167:139-48 https://www.ncbi.nlm.nih.gov/pubmed/31753130.
• 29.Ono Y, et al. Occlusion and brain function: mastication as a prevention of cognitive dysfunction. J Oral Rehabil. 2010;37(8):624-40 https://www.ncbi.nlm.nih.gov/pubmed/20236235.
• 30.Kubo KY, et al. Masticatory function and cognitive function. Okajimas Folia Anat Jpn. 2010;87(3):135-40 https://www.ncbi.nlm.nih.gov/pubmed/21174943.
• 31.Chen H, et al. Chewing Maintains Hippocampus-Dependent Cognitive Function. Int J Med Sci. 2015;12(6):502-9 https://www.ncbi.nlm.nih.gov/pubmed/26078711.
• 32.Azuma K, et al. Association between Mastication, the Hippocampus, and the HPA Axis: A Comprehensive Review. Int J Mol Sci. 2017;18(8) https://www.ncbi.nlm.nih.gov/pubmed/28771175.
• 33.Chuhuaicura P, et al. Mastication as a protective factor of the cognitive decline in adults: A qualitative systematic review. Int Dent J. 2019;69(5):334-40 https://www.ncbi.nlm.nih.gov/pubmed/31140598.
• 34.Lopez-Chaichio L, et al. Oral health and healthy chewing for healthy cognitive ageing: A comprehensive narrative review. Gerodontology. 2021;38(2):126-35 https://www.ncbi.nlm.nih.gov/pubmed/33179281.
• 35.Tada A, Miura H. Association between mastication and cognitive status: A systematic review. Arch Gerontol Geriatr. 2017;70:44-53 https://www.ncbi.nlm.nih.gov/pubmed/28042986.
• 36.Ahmed SE, et al. Influence of Dental Prostheses on Cognitive Functioning in Elderly Population: A Systematic Review. J Pharm Bioallied Sci. 2021;13(Suppl 1):S788-S94 https://www.ncbi.nlm.nih.gov/pubmed/34447202.
• 37.Tonsekar PP, et al. Periodontal disease, tooth loss and dementia: Is there a link? A systematic review. Gerodontology. 2017;34(2):151-63 https://www.ncbi.nlm.nih.gov/pubmed/28168759.
• 38.Nangle MR, Manchery N. Can chronic oral inflammation and masticatory dysfunction contribute to cognitive impairment? Curr Opin Psychiatry. 2020;33(2):156-62 https://www.ncbi.nlm.nih.gov/pubmed/31895157.
• 39.Nakamura T, et al. Oral dysfunctions and cognitive impairment/dementia. J Neurosci Res. 2021;99(2):518-28 https://www.ncbi.nlm.nih.gov/pubmed/33164225.
• 40.Weijenberg RAF, et al. Mind your teeth-The relationship between mastication and cognition. Gerodontology. 2019;36(1):2-7 https://www.ncbi.nlm.nih.gov/pubmed/30480331.
• 41.Asher S, et al. Periodontal health, cognitive decline, and dementia: A systematic review and meta-analysis of longitudinal studies. J Am Geriatr Soc. 2022;70(9):2695-709 https://www.ncbi.nlm.nih.gov/pubmed/36073186.
• 42.Lin CS. Revisiting the link between cognitive decline and masticatory dysfunction. BMC Geriatr. 2018;18(1):5 https://www.ncbi.nlm.nih.gov/pubmed/29304748.
• 43.Wu YT, et al. The changing prevalence and incidence of dementia over time – current evidence. Nat Rev Neurol. 2017;13(6):327-39 https://www.ncbi.nlm.nih.gov/pubmed/28497805.
• 44.Desai M, Park T. Deprescribing practices in Canada: A scoping review. Can Pharm J (Ott) 2022;155(5):249-57. doi: 10.1177/17151635221114114.
• 45.Kakkar M, Barmak AB, Arany S. Anticholinergic medication and dental caries status in middle-aged xerostomia patients-a retrospective study. J Dent Sci 2022;17(3):1206-11. doi: 10.1016/j.jds.2021.12.014.
• 46.Kaur M, Himadi E, Chi DL. Prevalence of xerostomia in an adolescent inpatient psychiatric clinic: a preliminary study. Special Care Dent 2016;36:60-5.
• 47.Okamoto A, Miyachi H, Tanaka K et al. Relationship between xerostomia and psychotropic drugs in patients with schizophrenia: evaluation using an oral moisture meter. J Clin Pharm Ther 2016;41(6):684-8. doi: 10.1111/jcpt.12449.
• 48.Centers for Disease Control and Prevention. Autism Spectrum Disorder (ASD). Data & Statistics on Autism Spectrum Disorder. https://www.cdc.gov/ncbddd/autism/data.html.
• 49.Loo CY, Graham RM, Hughes CV. The caries experience and behavior of dental patients with autism spectrum disorder. J Am Dent Assoc 2008;139(11):1518-24.
• 50.Allison KH, Hammond MEH, Dowsett M et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol 2020 38:12, 1346-66. https://ascopubs.org/doi/10.1200/JCO.19.02309.
• 51.Feinstein JA, Feudtner C, Kempe A, Orth LE. Anticholinergic Medications and Parent-Reported Anticholinergic Symptoms in Neurologically Impaired Children. J Pain Symptom Manage 2022:S0885-3924(22)00952-6. doi: 10.1016/j.jpainsymman.2022.10.013.
• 52.Ikram M, Shaikh NF, Sambamoorthi U. A Linear Decomposition Approach to Explain Excess Direct Healthcare Expenditures Associated with Pain Among Adults with Osteoarthritis. Health Serv Insights 2022;15:11786329221133957. doi: 10.1177/11786329221133957.
• 53.Bevilacqua KG, Brinkley C, McGowan J et al. “We are Getting Those Old People Things.” Polypharmacy Management and Medication Adherence Among Adult HIV Patients with Multiple Comorbidities: A Qualitative Study. Patient Prefer Adherence 2022;16:2773-80. doi: 10.2147/PPA.S382005.
• 54.Chertcoff A, Ng HS, Zhu F et al. Polypharmacy and multiple sclerosis: A population-based study. Mult Scler 2022:13524585221122207. doi: 10.1177/13524585221122207.
• 55.Aguglia A, Natale A, Fusar-Poli L et al. Complex polypharmacy in bipolar disorder: Results from a real-world inpatient psychiatric unit. Psychiatry Res 2022;318:114927. doi: 10.1016/j.psychres.2022.114927.
• 56.Cheng JJ, Azizoddin AM, Maranzano MJ et al. Polypharmacy in Oncology. Clin Geriatr Med 2022;38(4):705-14. doi: 10.1016/j.cger.2022.05.010.
• 57.Betts AC, Murphy CC, Shay LA et al. Polypharmacy and medication fill nonadherence in a population-based sample of adolescent and young adult cancer survivors, 2008-2017. J Cancer Surviv 2022 Nov 8. doi: 10.1007/s11764-022-01274-0.
• 58.Macrotrends. U.S. Life Expectancy 1950-2023. https://www.macrotrends.net/countries/USA/united-states/life-expectancy.